{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:18Z","timestamp":1793899698288,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["AB24010094"],"award-info":[{"award-number":["AB24010094"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260241"],"award-info":[{"award-number":["82260241"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2026GXNSFAA00640608"],"award-info":[{"award-number":["2026GXNSFAA00640608"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2020GXNSFAA259053"],"award-info":[{"award-number":["2020GXNSFAA259053"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Medical and Health Appropriate Technology Development and Application Project","award":["S2022091"],"award-info":[{"award-number":["S2022091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14199-w","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:12:59Z","timestamp":1791468779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of PCSK9 inhibitors combined with statins in acute ischemic stroke: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"273","author":[{"given":"Xiaozuo","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linkun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-9763","authenticated-orcid":false,"given":"Man","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"14199_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/17474930241308142","volume":"20","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, Grupper MF, Rautalin I (2025) World Stroke Organization: global stroke fact sheet 2025. Int J Stroke 20:132\u2013144. https:\/\/doi.org\/10.1177\/17474930241308142","journal-title":"Int J Stroke"},{"key":"14199_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2026.104768","volume":"36","author":"P Li","year":"2026","unstructured":"Li P, Tan J, Zhang C, Liu Y, Lin Y (2026) Clinical outcomes and safety profile of early low-density lipoprotein cholesterol target attainment in patients with atherosclerotic cerebral infarction: a prospective cohort study. Nutr Metab Cardiovasc Dis 36:104768. https:\/\/doi.org\/10.1016\/j.numecd.2026.104768","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"14199_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL (2024) The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol 21:701\u2013716. https:\/\/doi.org\/10.1038\/s41569-024-01039-5","journal-title":"Nat Rev Cardiol"},{"key":"14199_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40263-025-01222-3","volume":"39","author":"M Gupta","year":"2025","unstructured":"Gupta M, Smokovski I, Chatzis DG, Spring KJ, Mehndiratta MM, Beran RG, Bhaskar SMM (2025) Statins in acute ischemic stroke: mechanisms, resistance, and precision strategies for neurovascular and cognitive protection. CNS Drugs 39:1083\u20131107. https:\/\/doi.org\/10.1007\/s40263-025-01222-3","journal-title":"CNS Drugs"},{"key":"14199_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2024.1433","volume":"81","author":"Y Gao","year":"2024","unstructured":"Gao Y, Jiang L, Pan Y, Chen W, Jing J, Wang C, Johnston SC, Amarenco P, Bath PM, Yang Y, Wang T, Han S, Meng X, Lin J, Zhao X, Liu L, Zhao J, Li Y, Zang Y, Zhang S, Yang H, Yang J, Wang Y, Li D, Wang Y, Liu D, Kang G, Wang Y, Wang Y (2024) Immediate- or delayed-intensive statin in acute cerebral ischemia: the INSPIRES randomized clinical trial. JAMA Neurol 81:741\u2013751. https:\/\/doi.org\/10.1001\/jamaneurol.2024.1433","journal-title":"JAMA Neurol"},{"key":"14199_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.21037\/atm-21-1467","volume":"9","author":"HQ Gu","year":"2021","unstructured":"Gu HQ, Yang KX, Yang X, Wang CJ, Lyu TJ, Zhao XQ, Wang YL, Liu LP, Liu C, Li H, Jiang Y, Wang YJ, Li ZX (2021) Guideline-directed low-density lipoprotein management in high-risk ischemic stroke or transient ischemic attack admissions in China from 2015 to 2019. Ann Transl Med 9:1224. https:\/\/doi.org\/10.21037\/atm-21-1467","journal-title":"Ann Transl Med"},{"key":"14199_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.023328","volume":"11","author":"E Punch","year":"2022","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M (2022) Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 11:e023328. https:\/\/doi.org\/10.1161\/jaha.121.023328","journal-title":"J Am Heart Assoc"},{"key":"14199_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/m15-2994","volume":"164","author":"EP Navarese","year":"2016","unstructured":"Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O\u2019Connor C, Gurbel PA (2016) Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med 164:600\u2013607. https:\/\/doi.org\/10.7326\/m15-2994","journal-title":"Ann Intern Med"},{"key":"14199_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamacardio.2016.5395","volume":"2","author":"NR Desai","year":"2017","unstructured":"Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS (2017) Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol 2:556\u2013560. https:\/\/doi.org\/10.1001\/jamacardio.2016.5395","journal-title":"JAMA Cardiol"},{"key":"14199_CR10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"14199_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/circulationaha.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, L\u00f3pez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146:1109\u20131119. https:\/\/doi.org\/10.1161\/circulationaha.122.061620","journal-title":"Circulation"},{"key":"14199_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Sch\u00fcnemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"14199_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.048729","volume":"15","author":"YT Pan","year":"2025","unstructured":"Pan YT, Tsai YH, Weng HH, Lee JD, Yang JT, Lin LC, Huang YC (2025) Add-on PCSK9 inhibitor therapy for acute stroke due to intracranial atherosclerosis: a randomized clinical trial. J Am Heart Assoc 15:e048729. https:\/\/doi.org\/10.1161\/JAHA.125.048729","journal-title":"J Am Heart Assoc"},{"key":"14199_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-024-01145-5","volume":"39","author":"W Tian","year":"2025","unstructured":"Tian W, Cao H, Li X, Gong X, Yu X, Li D, Xie J, Bai Y, Zhang D, Li X, Xu P, Liu J, Zhang B, Ji X, Dong H (2025) Adjunctive PCSK9 inhibitor evolocumab in the prevention of early neurological deterioration in non-cardiogenic acute ischemic stroke: a multicenter, prospective, randomized, open-label, clinical trial. CNS Drugs 39:197\u2013208. https:\/\/doi.org\/10.1007\/s40263-024-01145-5","journal-title":"CNS Drugs"},{"issue":"14","key":"14199_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3969\/j.issn.1005-8982.2024.14.010","volume":"34","author":"J Yu","year":"2024","unstructured":"Yu J, Jiang K, Guo Y (2024) Efficacy analysis of intermittent alirocumab combined with atorvastatin in elderly statin-intolerant patients with cerebral infarction and hyperlipidemia. China J Mod Med 34(14):66\u201370. https:\/\/doi.org\/10.3969\/j.issn.1005-8982.2024.14.010","journal-title":"China J Mod Med"},{"issue":"17","key":"14199_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3969\/j.issn.1674-4721.2025.17.06","volume":"32","author":"JH Guan","year":"2025","unstructured":"Guan JH, Ni YF (2025) Application efficacy of alirocumab in patients with cerebral infarction and its effects on blood lipids and carotid plaques. China Mod Med 32(17):28-31,36. https:\/\/doi.org\/10.3969\/j.issn.1674-4721.2025.17.06","journal-title":"China Mod Med"},{"issue":"6","key":"14199_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3760\/cma.j.cn113694-20230905-00112","volume":"57","author":"X Gong","year":"2024","unstructured":"Gong X, Yu X, Pu L, Jiao Y, Liu L, Cao H, Ji X (2024) Effects of proprotein convertase subtilisin\/kexin type 9 inhibitor combined with rosuvastatin on blood lipid levels and short-term prognosis in patients with acute ischemic stroke. Chin J Neurol 57(6):625\u2013633. https:\/\/doi.org\/10.3760\/cma.j.cn113694-20230905-00112","journal-title":"Chin J Neurol"},{"issue":"12","key":"14199_CR18","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.3969\/j.issn.1005-9202.2025.12.005","volume":"45","author":"CL Yang","year":"2025","unstructured":"Yang CL, Yang YH, Zhang Q (2025) Effects of evolocumab combined with rosuvastatin on blood lipids, inflammatory factors and prognosis in elderly patients with acute cerebral infarction. Chin J Gerontol 45(12):2834\u20132837. https:\/\/doi.org\/10.3969\/j.issn.1005-9202.2025.12.005","journal-title":"Chin J Gerontol"},{"key":"14199_CR19","unstructured":"Shi L (2025) Clinical study of evolocumab combined with statins in the treatment of acute large artery atherosclerotic ischemic stroke. Master's thesis, Inner Mongolia Medical University"},{"issue":"8","key":"14199_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3969\/j.issn.1007-614x.2025.08.019","volume":"41","author":"H Li","year":"2025","unstructured":"Li H (2025) Clinical efficacy of alirocumab combined with rosuvastatin and aspirin in atherosclerotic ischemic stroke. Chin Community Doct 41(8):57\u201359. https:\/\/doi.org\/10.3969\/j.issn.1007-614x.2025.08.019","journal-title":"Chin Community Doct"},{"issue":"21","key":"14199_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.19335\/j.cnki.2096-1219.2024.21.029","volume":"10","author":"JL He","year":"2024","unstructured":"He JL (2024) Effects of alirocumab on blood lipids and serum apolipoprotein A1 levels in patients with acute cerebral infarction. Smart Healthc 10(21):94\u201396. https:\/\/doi.org\/10.19335\/j.cnki.2096-1219.2024.21.029","journal-title":"Smart Healthc"},{"key":"14199_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K (2023) Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther 249:108480. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108480","journal-title":"Pharmacol Ther"},{"key":"14199_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","volume":"30","author":"C Barale","year":"2020","unstructured":"Barale C, Bonomo K, Frascaroli C, Morotti A, Guerrasio A, Cavalot F, Russo I (2020) Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up. Nutr Metab Cardiovasc Dis 30:282\u2013291. https:\/\/doi.org\/10.1016\/j.numecd.2019.09.012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"14199_CR24","first-page":"274","volume":"33","author":"SA Kazi","year":"2021","unstructured":"Kazi SA, Siddiqui M, Majid S (2021) Stroke outcome prediction using admission NIHSS in anterior and posterior circulation stroke. J Ayub Med Coll Abbottabad 33:274\u2013278","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"14199_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/s1474-4422(22)00519-1","volume":"22","author":"G Tsivgoulis","year":"2023","unstructured":"Tsivgoulis G, Katsanos AH, Sandset EC, Turc G, Nguyen TN, Bivard A, Fischer U, Khatri P (2023) Thrombolysis for acute ischaemic stroke: current status and future perspectives. Lancet Neurol 22:418\u2013429. https:\/\/doi.org\/10.1016\/s1474-4422(22)00519-1","journal-title":"Lancet Neurol"},{"key":"14199_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu T, Wiklund O (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"14199_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12020332","volume":"12","author":"B Kollar","year":"2024","unstructured":"Kollar B, Siarnik P, Konarikova K, Oravec S, Klobucka S, Klobucnikova K, Poddany M, Radikova Z, Janubova M, Turcani P, Gajdosova L, Zitnanova I (2024) The interplay of dyslipidemia, oxidative stress, and clinical outcomes in acute ischemic stroke patients with and without coronary artery disease. Biomedicines 12:332. https:\/\/doi.org\/10.3390\/biomedicines12020332","journal-title":"Biomedicines"},{"key":"14199_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"14199_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jacc.2024.06.035","volume":"84","author":"D Zahger","year":"2024","unstructured":"Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Jukema JW, Kiss RG, Harrington RA, Moriarty PM, Scemama M, Manvelian G, Pordy R, White HD, Zeiher AM, Fazio S, Geba GP, Steg PG (2024) Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome. J Am Coll Cardiol 84:994\u20131006. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.035","journal-title":"J Am Coll Cardiol"},{"key":"14199_CR30","doi-asserted-by":"publisher","DOI":"10.1017\/s2045796021000664","volume":"30","author":"P Cuijpers","year":"2021","unstructured":"Cuijpers P, Griffin JW, Furukawa TA (2021) The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note. Epidemiol Psychiatr Sci 30:e78. https:\/\/doi.org\/10.1017\/s2045796021000664","journal-title":"Epidemiol Psychiatr Sci"},{"key":"14199_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F (2022) LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med 134:752\u2013762. https:\/\/doi.org\/10.1080\/00325481.2022.2117498","journal-title":"Postgrad Med"},{"key":"14199_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cld.2019.09.007","volume":"24","author":"L Meurer","year":"2020","unstructured":"Meurer L, Cohen SM (2020) Drug-induced liver injury from statins. Clin Liver Dis 24:107\u2013119. https:\/\/doi.org\/10.1016\/j.cld.2019.09.007","journal-title":"Clin Liver Dis"},{"key":"14199_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082922","volume":"12","author":"M Bellino","year":"2023","unstructured":"Bellino M, Galasso G, Silverio A, Tedeschi M, Formisano C, Romei S, Esposito L, Cancro FP, Vassallo MG, Accarino G, Verdoia M, Di Muro FM, Vecchione C, De Luca G (2023) Soluble PCSK9 inhibition: indications, clinical impact, new molecular insights and practical approach-where do we stand? J Clin Med 12:2922. https:\/\/doi.org\/10.3390\/jcm12082922","journal-title":"J Clin Med"},{"issue":"11","key":"14199_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70451","volume":"6","author":"J Kuang","year":"2025","unstructured":"Kuang J, Hao L, Zhang M, Yang Z (2025) Proprotein convertase subtilisin\/kexin type 9 (PCSK9): the multifaceted biology, diseases, and pharmaceutical interventions. MedComm 6(11):e70451. https:\/\/doi.org\/10.1002\/mco2.70451","journal-title":"MedComm"},{"key":"14199_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075837","volume":"383","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, Cho HJ, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK, LODESTAR investigators (2023) Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ 383:e075837. https:\/\/doi.org\/10.1136\/bmj-2023-075837","journal-title":"BMJ"},{"key":"14199_CR36","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS (2021) 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 52:e364\u2013e467. https:\/\/doi.org\/10.1161\/STR.0000000000000375","journal-title":"Stroke"},{"key":"14199_CR37","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, ESC\/EAS Scientific Document Group (2025) 2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46:4359\u20134378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"key":"14199_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.10707","volume":"9","author":"C Kellogg","year":"2026","unstructured":"Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE (2026) Theoretical cost-effectiveness of PCSK9 inhibitors in stroke due to intracranial atherosclerosis. JAMA Netw Open 9:e2610707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.10707","journal-title":"JAMA Netw Open"},{"key":"14199_CR39","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X450809260715104225","author":"F Epelde","year":"2026","unstructured":"Epelde F (2026) PCSK9 inhibitors for secondary prevention in patients with prior stroke: a PRISMA-guided systematic review. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/011570159X450809260715104225","journal-title":"Curr Neuropharmacol"},{"key":"14199_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2026.05.189","volume":"20","author":"K Ogunniyi","year":"2026","unstructured":"Ogunniyi K, Ogieuhi J, Ugwu C, Ahmed Z, Awoyemi T (2026) Proprotein convertase subtilisin\/kexin type 9 inhibitors versus bempedoic acid in older statin-intolerant patients with uncontrolled LDL-cholesterol. J Clin Lipidol 20:e122. https:\/\/doi.org\/10.1016\/j.jacl.2026.05.189","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14199-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:05:38Z","timestamp":1793898338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14199-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14199"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14199-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors affirm that there are no conflicts of interest related to the publication of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"652"}}